Autopsy report · NCT05238831

SMMART Adaptive Clinical Treatment (ACT) Trial

“Withdrawn due to a change in therapeutic interventions.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

OHSU Knight Cancer Institute

Sponsor type

University, hospital or other

Conditions

Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma

Interventions

Alectinib; Alpelisib; Anastrozole; Atezolizumab; Bevacizumab; Biopsy

Participants

0

Trials that died the same way

• Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
  “Withdrawn due to toxicity” (74% match in meaning)
• The Effects of Rimonabant, on Weight and Metabolic Risk Factors
  “Withdrawn due to medication withdrawal from the EMEA” (69% match in meaning)
• Lapatinib and Bortezomib in Patients With Advanced Malignancies
  “Drug support withdrawn” (69% match in meaning)
• HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19
  “Withdrawn due to lack of study centers interested in participating.” (69% match in meaning)
• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.